Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alliant Pharmaceuticals
Alliant Pharmaceuticals re-launches Methylin chewable tablets
July 4th, 2006
Alliant Pharmaceuticals, Inc., announced the re-introduction of Methylin Chewable Tablets. The product is the first, and only, chewable tablet for use in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children. Methylin is considered the gold standard for treating children for ADHD. ADHD is a disorder of the brain in which the individual repeatedly exhibits inappropriate impulsivity and/or inattention. According to the Attention Deficit Disorder Association, an estimated 5% to 10% of school age children, and an estimated 3-6% of adults suffer from ADHD. Studies show that more than 50% of children ages 12 and...
Source: Pharma Law Weekly (2006-07-04)
|
